Actively Recruiting
Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion
Led by Jinling Hospital, China · Updated on 2026-04-30
386
Participants Needed
1
Research Sites
162 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Stroke is one of the most important diseases endangering the health and quality of life of Chinese people. Acute ischemic stroke (AIS) is commonly caused by cerebrovascular stenosis or occlusion. The most effective treatment for AIS is timely and successful angiographic reperfusion. Due to the large diameter and obvious positioning of bilateral femoral arteries, the transfemoral artery (TFA) using Seldinger's technique has been the most commonly used approach for endovascular treatment. However, recent studies have suggested that the radial artery is an ideal puncture site for cerebrovascular intervention. Small sample studies have confirmed that endovascular recanalization for acute anterior circulation large vessel occlusion via TRA has been safe and effective. Still, there are some complex approaches needed to be converted to TFA. There has been no difference in total operation duration and fluoroscopy time between TRA and TFA, but the TRA group had higher radiation dose and shorter hospital stays than the TFA group. In addition, TRA tends to be more convenient than TFA, especially for posterior circulation lesions. However, the current studies are based on a single center with a small sample size, and there has been still a lack of large-sample randomized controlled experiments to verify the safety and effectiveness of posterior endovascular recanalization via TRA.
CONDITIONS
Official Title
Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute ischemic stroke in the posterior circulation confirmed by symptoms and imaging
- Basilar artery occlusion confirmed by CTA, MRA, or DSA
- Age 18 years or older
- Time from symptom onset to randomization within 24 hours
- Baseline NIHSS score 10 or higher before randomization
- Intact dual circulation of the hand assessed by modified Allen's test
- Written informed consent from patient or legally authorized representative
You will not qualify if you...
- Pre-stroke disability with modified Rankin Scale score 3 or higher
- Pregnant or lactating women
- Allergy to contrast agents or nitinol devices
- Participation in other clinical trials
- Blood pressure above 185/110 mmHg uncontrolled by medication
- Known bleeding disorders or oral anticoagulant therapy with INR above 1.7
- Blood glucose below 50 mg/dL or above 400 mg/dL
- Platelet count below 50 x 10^9/L or hematocrit below 25%
- Life expectancy less than 1 year
- Lost to follow-up within 90 days (no fixed residence, overseas patients, etc.)
- Stroke within 48 hours after coronary or cerebrovascular intervention or major surgery
- Signs of central nervous system vasculitis
- Nervous system diseases or mental disorders interfering with disease assessment
- Conditions preventing radial or femoral artery puncture or instrument delivery, such as infection, anatomical abnormalities, or prior surgeries
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Neurology, Jinling Hospital
Nanjing, Jiangsu, China, 210002
Actively Recruiting
Research Team
R
Rui Liu, MD
CONTACT
X
Xinfeng Liu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here